Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Doxorubicin, DNA torsion, and chromatin dynamics.

Authors: Yang, F  Teves, SS  Kemp, CJ  Henikoff, S 
Citation: Yang F, etal., Biochim Biophys Acta. 2014 Jan;1845(1):84-9. doi: 10.1016/j.bbcan.2013.12.002. Epub 2013 Dec 19.
Pubmed: (View Article at PubMed) PMID:24361676
DOI: Full-text: DOI:10.1016/j.bbcan.2013.12.002

Doxorubicin is one of the most important anti-cancer chemotherapeutic drugs, being widely used for the treatment of solid tumors and acute leukemias. The action of doxorubicin and other anthracycline drugs has been intensively investigated during the last several decades, but the mechanisms that have been proposed for cell killing remain disparate and controversial. In this review, we examine the proposed models for doxorubicin action from the perspective of the chromatin landscape, which is altered in many types of cancer due to recurrent mutations in chromatin modifiers. We highlight recent evidence for effects of anthracyclines on DNA torsion and chromatin dynamics that may underlie basic mechanisms of doxorubicin-mediated cell death and suggest new therapeutic strategies for cancer treatment.


Molecular Pathway Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 10395267
Created: 2015-08-27
Species: All species
Last Modified: 2015-08-27
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.